JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on Immunovant (NASDAQ:IMVT) but lowers the price target from $51 to $46.
August 08, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Brian Cheng maintains an Overweight rating on Immunovant but lowers the price target from $51 to $46.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100